Patent intelligence · US
US 11174232
Substituted heterocyclyl derivatives as CDK inhibitors
Substituted heterocyclyl derivatives as CDK inhibitors
Patent details — US 11174232
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 16, 2021
- Expiration
- Nov 11, 2041
- Applicant
- Aurigene Discovery Technologies Limited
- Claims
- 14
- CPC classes
- A61K, A61K31/415, A61K31/4155, A61K31/416
Quick answer
US 11174232 (Substituted heterocyclyl derivatives as CDK inhibitors) is held by Aurigene Discovery Technologies Limited. Status: granted. Granted Nov 16, 2021. Expires Nov 11, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aurigene Discovery Technologies Limited
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/415, A61K31/4155, A61K31/416, A61K31/4439, A61K31/454
More from Aurigene Discovery Technologies Limited
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 11174232?
US 11174232 (Substituted heterocyclyl derivatives as CDK inhibitors) is held by Aurigene Discovery Technologies Limited. Status: granted. Granted Nov 16, 2021. Expires Nov 11, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11174232?
Aurigene Discovery Technologies Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 11174232 expire?
Our index shows an expiration date of Nov 11, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.